Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Adashek · SciRah

Researcher profile · Semantic Scholar

J. Adashek

Share profile

J. Adashek — researcher profile on SciRah

h-index: 27
Works: 121
Citations: 2,474

Most-cited papers

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
S. Kato, Ki Hwan Kim, Hyo-Jeong Lim, A. Boichard +18 more
2020Nature Communications259 citations Open access
Semantic Scholar
SMARCA4: Implications of an altered chromatin-remodeling gene for cancer development and therapy
Kristina Mardinian, J. Adashek, G. Botta, S. Kato +1 more
2021Molecular Cancer Therapeutics157 citations Open access
Semantic Scholar
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
J. Adashek, I. Subbiah, I. Matos, E. Garralda +3 more
2020Trends in Cancer114 citations Open access
Semantic Scholar
Phase I trials as valid therapeutic options for patients with cancer
J. Adashek, P. LoRusso, D. Hong, R. Kurzrock
2019Nature Reviews Clinical Oncology109 citations Open access
Semantic Scholar
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
J. Adashek, V. Subbiah, R. Kurzrock
2020Trends in Cancer97 citations Open access
Semantic Scholar
Caring for the caregiver: a systematic review characterising the experience of caregivers of older adults with advanced cancers
J. Adashek, I. Subbiah
2020ESMO Open96 citations Open access
Semantic Scholar
Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening
J. Adashek, F. Janku, R. Kurzrock
2021Cancers86 citations Open access
Semantic Scholar
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
J. Adashek, S. Kato, R. Ferrara, Giuseppe Lo Russo +1 more
2019The Oncologist73 citations Open access
Semantic Scholar
The abscopal effect in patients with cancer receiving immunotherapy
B. Nelson, J. Adashek, S. Lin, V. Subbiah
2023i Medicina71 citations Open access
Semantic Scholar
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
V. Tateo, P. Marchese, V. Mollica, F. Massari +2 more
2023Pharmaceuticals70 citations Open access
Semantic Scholar
A phase 1 trial of SGN‐CD70A in patients with CD70‐positive, metastatic renal cell carcinoma
S. Pal, A. Forero-Torres, John A. Thompson, J. Morris +11 more
2019Cancer62 citations Open access
Semantic Scholar
Perioperative Immune Checkpoint Inhibition in Early-Stage Non-Small Cell Lung Cancer: A Review.
A. Desai, J. Adashek, J. Reuss, H. West +1 more
2022JAMA Oncology54 citations
Semantic Scholar
Understanding genomics and the immune environment of penile cancer to improve therapy
A. Aydin, J. Chahoud, J. Adashek, M. Azizi +4 more
2020Nature reviews. Urology50 citations
Semantic Scholar
The paradox of cancer genes in non-malignant conditions: implications for precision medicine
J. Adashek, S. Kato, S. Lippman, R. Kurzrock
2020Genome Medicine49 citations Open access
Semantic Scholar
Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload
A. Kondrashov, Surendra Sapkota, Aditya Sharma, Ivy Riano +2 more
2023Pharmaceutics44 citations Open access
Semantic Scholar
Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice
J. K. Hicks, Rachel Howard, P. Reisman, J. Adashek +11 more
2021JCO Precision Oncology43 citations Open access
Semantic Scholar
Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
N. Bevins, R. Okamura, M. Montesion, J. Adashek +2 more
2022Journal of Immunotherapy and Precision Oncology38 citations Open access
Semantic Scholar
Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
J. Adashek, Arjun K. Menta, N. Reddy, A. Desai +2 more
2022Molecular Cancer Therapeutics38 citations Open access
Semantic Scholar
Hallmarks of RET and co-occurring genomic alterations in RET-aberrant cancers
J. Adashek, A. Desai, Alexander Y. Andreev-Drakhlin, J. Roszik +2 more
2021Molecular Cancer Therapeutics38 citations Open access
Semantic Scholar
Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
J. Adashek, R. Jain, Jing-Song Zhang
2019Cells37 citations Open access
Semantic Scholar
Missing the target in cancer therapy
J. Adashek, A. Goloubev, S. Kato, R. Kurzrock
2021Nature Cancer34 citations Open access
Semantic Scholar
Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A Review of the Evidence Using Second-Generation p-Values
J. Adashek, G. Genovese, N. Tannir, P. Msaouel
2020Cancer Treatment and Research Communications34 citations Open access
Semantic Scholar
Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics
S. Kato, J. Adashek, J. Shaya, R. Okamura +4 more
2021Clinical Cancer Research33 citations Open access
Semantic Scholar
Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
J. Shaya, S. Kato, J. Adashek, Hitendra R. H. Patel +4 more
2023npj Genomic Medicine31 citations Open access
Semantic Scholar
Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens
S. Kato, R. Okamura, J. Adashek, Noor Khalid +4 more
2021JCI Insight31 citations Open access
Semantic Scholar
If it’s a target, it’s a pan-cancer target: Tissue is not the issue
J. Adashek, S. Kato, J. Sicklick, Scott M. Lippman +1 more
2024Cancer Treatment Reviews30 citations Open access
Semantic Scholar
LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics
J. Adashek, S. Kato, D. Nishizaki, H. Miyashita +8 more
2023Cancer Medicine25 citations Open access
Semantic Scholar
Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?
Amol Gupta, R. Kurzrock, J. Adashek
2023Cancers25 citations Open access
Semantic Scholar
Examining Public Communication About Kidney Cancer on Twitter.
M. Sedrak, M. Salgia, Cristiane Decat Bergerot, K. Ashing-Giwa +6 more
2019JCO Clinical Cancer Informatics24 citations Open access
Semantic Scholar
15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis
Mahati Paravathaneni, H. Safa, Vidhu B. Joshi, M. Tamil +12 more
2024EClinicalMedicine21 citations Open access
Semantic Scholar
Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers
B. Nelson, J. Adashek, A. Sheth, V. Subbiah
2023Molecular Cancer Therapeutics21 citations Open access
Semantic Scholar
Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting
S. Kato, Bing Li, J. Adashek, S. Cha +13 more
2022Oncoimmunology20 citations Open access
Semantic Scholar
Back to the Future: In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments.
P. Aguiar, J. Adashek, F. Roitberg, C. M. Noia Barreto +2 more
2019Value in Health Regional Issues20 citations Open access
Semantic Scholar
Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer
J. Adashek, Yadis M Arroyo-Martinez, Arjun K. Menta, R. Kurzrock +1 more
2020Frontiers in Oncology19 citations Open access
Semantic Scholar
Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies
A. M. Shayeb, R. Kurzrock, J. Adashek, S. Kato
2023JCO Precision Oncology16 citations Open access
Semantic Scholar
Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials
Christopher W. Szeto, R. Kurzrock, S. Kato, A. Goloubev +4 more
2022ESMO Open16 citations Open access
Semantic Scholar
Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place
J. Adashek, R. Kurzrock
2023npj Precision Oncology14 citations Open access
Semantic Scholar
Challenges and prospects of CSF1R targeting for advanced malignancies.
Ann Moeller, R. Kurzrock, G. Botta, J. Adashek +7 more
2023American Journal of Cancer Research14 citations
Semantic Scholar
Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma.
J. Adashek, M. Salgia, E. Posadas, R. Figlin +1 more
2019Clinical Genitourinary Cancer14 citations
Semantic Scholar
Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer
J. Adashek, Chinmayi Pandya, N. Maragakis, Pradip De +3 more
2024BMC Medicine13 citations
Semantic Scholar
Are Cancer Patients at Higher Risk of Death With COVID-19?
J. Adashek, J. Hajjar, R. Chemaly, R. Kurzrock
2020Journal of Immunotherapy and Precision Oncology13 citations Open access
Semantic Scholar
Extramammary Paget's disease: what do we know and how do we treat?
J. Adashek, A. Leonard, Samantha Nealon, Arvind Krishnan +3 more
2019The Canadian journal of urology13 citations
Semantic Scholar
Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity
Jung-Wha Lim, R. Kurzrock, D. Nishizaki, H. Miyashita +8 more
2023Cancer Medicine12 citations Open access
Semantic Scholar
Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma.
N. Mason, Vidhu B. Joshi, J. Adashek, Youngchul Kim +9 more
2023European Urology Oncology12 citations Open access
Semantic Scholar
Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
J. Adashek, Surendra Sapkota, Rodrigo de Castro Luna, T. Seiwert
2023npj Precision Oncology12 citations Open access
Semantic Scholar
Considering molecular alterations as pan-cancer tissue-agnostic targets
J. Adashek, S. Kato, J. Sicklick, Scott M. Lippman +1 more
2023Nature Cancer11 citations Open access
Semantic Scholar
Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma
Yu-Meng Zhang, Premsai Kumar, J. Adashek, W. P. Skelton +5 more
2022Cells11 citations Open access
Semantic Scholar
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response
H. Persha, S. Kato, P. De, J. Adashek +3 more
2022Journal of Hematology & Oncology11 citations Open access
Semantic Scholar
Multi‐omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown
S. Kato, S. Gumas, J. Adashek, R. Okamura +3 more
2022Molecular Oncology11 citations Open access
Semantic Scholar
On target methods to induce abscopal phenomenon for Off‐Target effects: From happenstance to happenings
B. Nelson, J. Adashek, S. Lin, V. Subbiah
2022Cancer Medicine11 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Kurzrock×28
Invite
R. Kurzrock — researcher profile on SciRah
S. Kato×19
Invite
S. Kato — researcher profile on SciRah
J. Sicklick×9
Invite
J. Sicklick — researcher profile on SciRah
V. Subbiah×8
Invite
V. Subbiah — researcher profile on SciRah

×7

Invite

Suzanna Lee — researcher profile on SciRah

Invite

R. Okamura — researcher profile on SciRah

Invite

J. Chahoud — researcher profile on SciRah

Invite

G. Botta — researcher profile on SciRah

Arjun K. Menta×3

Invite

Arjun K. Menta — researcher profile on SciRah

Invite

B. Nelson — researcher profile on SciRah

Invite

A. Desai — researcher profile on SciRah

Scott M. Lippman×3

Invite

Scott M. Lippman — researcher profile on SciRah